In an interview, Dr. Ranee Mehra, Director of Head and Neck Medical Oncology at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center and professor of medicine at the ...
Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...
Chronic kidney disease (CKD) guidelines recommend early identification and intervention to delay the progression of CKD. The Kidney Disease: Improving Global Outcomes (KDIGO) heatmap is widely used ...
Epidermal growth factor receptor (EGFR) belongs to the HER/erbB family of receptor tyrosine kinases (RTKs), and is a prominent therapeutic target for non-small cell lung carcinomas (NSCLCs). Improper ...
NSCLC is the leading cause of cancer deaths globally, with EGFR mutations being a common feature in these cancers. Osimertinib has shown significant improvements in progression-free survival for ...
Researchers at the Medical University of Vienna have described a mechanism in metastatic colorectal cancer that has received little attention to date: A key target of existing therapies, the so-called ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Hosted on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
For patients living with non-small cell lung cancer (NSCLC), recent treatment developments are providing hope and potentially making the treatment process itself easier. A subcutaneous version, or a ...
Incorporating β2-microglobulin and β-trace protein filtration markers may improve GFR estimation in patients with solid tumors. Adding the novel endogenous filtration markers β2-microglobulin and ...
Over 80% of patients with lung cancer receive community care, risking gaps in care quality and delivery. ACCC's initiative identified barriers to biomarker testing and care delivery for early-stage ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We have a number of excellent frontline ...
The symptoms of many kidney diseases are not obvious. When symptoms do appear, there may have been a lot of damage done. For this reason, GFR is regarded as an important early warning marker. Doctors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results